Neumora Therapeutics IPO Presentation Deck

Focused on Building the Leading Global Brain Health Company Built at Scale Raised over $600M to date from leading investors Experienced company builders and leading neuroscience drug developers Leading Pipeline Focus on therapeutic candidates with novel MOAS Improve the efficiency of development and potentially increase the odds of clinical success Advancing seven novel programs Near-Term Catalysts Navacaprant entering Phase 3 pivotal studies in MDD in 3Q23 with readout expected in 2H24 NMRA-511 study in Alzheimer's disease agitation expected to initiate in 1H24 NMRA-266 IND submission expected in 4Q23 Advancing preclinical programs for NMRA- NMDA, NMRA-CK16, NMRA-NLRP3 and NMRA-GCASE Confidential 5

View entire presentation